CC-223 + erlotinib

**CC-223 + erlotinib** is a combination of two small molecules: CC-223, an oral inhibitor of mammalian target of rapamycin (mTOR), and erlotinib, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. CC-223 is designed to block signaling through the mTOR pathway, which is implicated in cancer cell growth, proliferation, and resistance mechanisms. Erlotinib inhibits the EGFR tyrosine kinase domain, preventing autophosphorylation and downstream signaling crucial for tumor growth and survival, especially in EGFR-mutated cancers. This combination aims to overcome resistance mechanisms seen with EGFR inhibition alone by simultaneously targeting parallel survival pathways active in cancer cells. The combination has been evaluated in phase 1/2 clinical trials, primarily for advanced solid tumors, including non-small cell lung cancer (NSCLC)[2].